#United States #SkinCure Oncology #GentleCure #Burr Ridge #NMSC

SkinCure Oncology's Commitment to Skin Cancer Awareness Month

As May approaches, SkinCure Oncology is taking the lead in promoting Skin Cancer Awareness Month, encouraging individuals to understand, detect, and treat nonmelanoma skin cancer (NMSC), which is the most prevalent form of cancer in the United States. With the alarming statistic that approximately 9,500 Americans are diagnosed with skin cancer every day, SkinCure Oncology aims to educate patients about effective treatment options available to them.

The GentleCure Experience™

Led by CEO Kerwin Brandt, SkinCure Oncology highlights the GentleCure Experience™, which offers a nonsurgical treatment option known as Image-Guided Superficial Radiation Therapy (IGSRT). This innovative method utilizes ultrasound imaging to direct low-level X-rays specifically to cancerous areas of the skin, effectively killing cancer cells. Impressively, the cure rate for patients treated with IGSRT has been reported to exceed 99%, showcasing its potential as not only a viable alternative to traditional methods like Mohs surgery but also as a superior choice to conventional non-image-guided treatments.

Scientific Backing and Advocacy

Fifteen peer-reviewed studies back the efficacy of this approach, underlining that IGSRT is a safe and effective first-line treatment for NMSC for appropriately selected patients. The consensus among experts accentuates the necessity for informed consent, ensuring patients are aware of all treatment options and remain engaged in the decision-making process regarding their healthcare.

Milestones in Treatment

Just this past January, SkinCure reached a significant milestone, successfully treating its 100,000th patient. This achievement not only underscores the growing acceptance of GentleCure among healthcare professionals but also demonstrates the demand for noninvasive solutions to skin cancer. Testimonials from satisfied patients have fueled the initiative, creating a shift towards a more patient-centric approach in dermatological care.

Introducing Next-Generation Technology

Continuing its commitment to innovation, SkinCure Oncology recently submitted its next-generation GentleBeam™ Image-Guided SRT technology for FDA clearance. This advancement aims to provide an even gentler and more precise treatment method, thereby expanding nonsurgical options for both patients and the healthcare community. While awaiting FDA approval, the anticipation surrounding GentleBeam illustrates the fast-evolving landscape of skin cancer treatments.

Nationwide Reach and Availability

Currently, more than 500 dermatologists across the U.S. offer the GentleCure Experience, with over half of these practices also providing Mohs surgery. This broad availability illustrates a significant shift in treatment preferences, with both patients and physicians expressing high levels of satisfaction with nonsurgical options like the GentleCure Experience. As awareness increases, SkinCure expects to see this non-invasive treatment option become even more prevalent within communities nationwide.

Learn More About Treatment Options

During Skin Cancer Awareness Month, SkinCure Oncology encourages individuals to educate themselves on the signs and symptoms of nonmelanoma skin cancer. It is imperative that patients understand their treatment options to make informed decisions about their health. To find more information or to schedule a consultation, visit SkinCureOncology.com and explore GentleCure.com for resources tailored to patients and consumers.

In conclusion, May serves as a crucial opportunity for education and awareness about nonmelanoma skin cancer. SkinCure Oncology stands at the forefront of this initiative, making a concerted effort to ensure that patients are well-informed and aware of the effective, non-invasive treatment options available to them.